17 February 2023
EMA/CVMP/51467/2023
Committee for Veterinary Medicinal Products (CVMP)

Summary of opinion[1] (post-authorisation)

Bravecto Plus

International non-proprietary name (INN): fluralaner / moxidectin

On 15 February 2023, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a group of variations to the terms of the marketing authorisation for the veterinary medicinal product Bravecto Plus. The marketing authorisation holder for this veterinary medicinal product is Intervet International B.V.

Bravecto Plus is currently authorised as spot-on solution for use in cats. The grouped variation is to add a new therapeutic indication for the prevention of aelurostrongylosis (by preventing the establishment of adult *Aelurostrongylus abstrusus* responsible for clinical disease) and to align the product information with version 9.0 of the QRD template.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union